Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Capital Expenditures (2020 - 2025)

Cytek Biosciences' Capital Expenditures history spans 6 years, with the latest figure at $4.0 million for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 5026.92% year-over-year to $4.0 million; the TTM value through Dec 2025 reached $4.1 million, up 2207.34%, while the annual FY2025 figure was $4.1 million, 2207.34% up from the prior year.
  • Capital Expenditures reached $4.0 million in Q4 2025 per CTKB's latest filing, up from -$2.3 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $8.2 million in Q4 2022 to a low of -$2.3 million in Q3 2025.
  • Average Capital Expenditures over 5 years is $981947.4, with a median of $505000.0 recorded in 2023.
  • The largest YoY upside for Capital Expenditures was 5026.92% in 2025 against a maximum downside of 9654.17% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at -$309000.0 in 2021, then surged by 2741.1% to $8.2 million in 2022, then tumbled by 81.62% to $1.5 million in 2023, then tumbled by 94.8% to $78000.0 in 2024, then soared by 5026.92% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Capital Expenditures are $4.0 million (Q4 2025), -$2.3 million (Q3 2025), and $2.2 million (Q2 2025).